FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

DIVISLAB Share Price Discussion

Divi's Laboratories Ltd.
NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Sector: Pharmaceuticals and health care

DIVISLAB Rating

4/5 (4 Ratings)
DIVISLAB Share Price *
2,169.35 -16.5 (-0.75%)
* (quote may be delayed)
Find answers to all your questions on live DIVISLAB message board: Is DIVISLAB buy or sell? Should I buy DIVISLAB shares? Why are DIVISLAB shares falling? Should I invest in DIVISLAB stock?

You can also check DIVISLAB share price target recommended by brokerages.

DIVISLAB Discussion Forum

@marketbull • Reputation: -12,848
DIVISLAB FEB20 2180 CE

Type
Buy
Instrument
DIVISLAB FEB20 2180 CE
Entry Price
₹35
Price@Trade
₹35
Target Price
₹70
Stop Price
₹0.05
Valid Till
Feb 20, 2020 3:20 PM
Margin
₹14,000 approx for 400 Qty
Status
Exited
Exit Price
₹25.95
Net P&L
-25.86% Loss
FIRST EARN THEN PAY
Like
reply
Reply (1)
Latest replies
BULL KING @marketbull
Feb 20 7:05 PM

Update
Exited
Exit Price
₹25.95
Net P&L
-25.86% Loss
@dreambig • Reputation: 2,020

Watch
Sell divislab cash
Sl 2208
Tgt 2180/2170
Like
reply
Reply (4)
Latest replies
DREAM BIG VIEW @dreambig
Feb 20 4:13 PM

Divislab cash
2198 to 2185
Near tgt 1
12 points till
Book as comforts
DREAM BIG VIEW @dreambig
Feb 20 6:59 PM

Divislab
2183 from 2198
Book as comforts
Gain in every call
DREAM BIG VIEW @dreambig
Feb 20 7:06 PM

Look at divislab guys
2198 to 2172.2 new day low
T1 dn 2180
Near final Tgt 2170
💸💸💸💸
25+ points dn
Book as comforts
DREAM BIG VIEW @dreambig
Feb 20 7:39 PM

Look at divislab guys
2198 to 2166 new day low
T1 dn 2180
final Tgt 2170
💸💸💸💸
28+ points dn
Book as comforts
All Tgt overachieved
@ENRITCHansraj • Reputation: -165,937
DIVISLAB FEB20 FUT

Type
Buy
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,220
Price@Trade
₹2,214.95
Target Price
₹2,260
Stop Price
₹2,200
Valid Till
Feb 20, 2020 3:20 PM
Status
Exited before entry
Like
reply
Reply (1)
Latest replies

Update
Exited before entry
Price @ Update
₹2,172.7
@RISHABHTYAGI • Reputation: 4,623

**Divislab fut sell below 2134**
Like
reply
Reply
@dreambig • Reputation: 2,020

Buy divislab lab cash
2157-21558
Sl 2147
Tgt 2167/2177/2187++
Like
reply
Reply (2)
Latest replies
DREAM BIG VIEW @dreambig
Feb 18 4:55 PM

2150.3 to 2160.7
DREAM BIG VIEW @dreambig
Feb 18 11:38 PM

2180 from 2150
@tsr • Reputation: 1,822
DIVISLAB FEB20 FUT

Type
Sell
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,152
Price@Trade
₹2,151.05
Target Price
₹2,132
Stop Price
₹2,172
Valid Till
Feb 18, 2020 3:20 PM
Margin
₹152,154.8 approx for 400 Qty
Status
Exited
Exit Price
₹2,145.15
Net P&L
1.8% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 18 4:25 PM

Update
Trade Entered
Entry Price
₹2,152
rahul @tsr
Feb 18 4:28 PM

Update
Exited
Exit Price
₹2,145.15
Net P&L
1.8% Profit
@tsr • Reputation: 1,822
DIVISLAB FEB20 FUT

Type
Sell
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,150
Price@Trade
₹2,147.25
Target Price
₹2,135
Stop Price
₹2,165
Valid Till
Feb 18, 2020 3:20 PM
Margin
₹152,157.63 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹2,165
Net P&L
-3.94% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 18 4:16 PM

Update
Trade Entered
Entry Price
₹2,150
TrackerBot @trackerbot
Feb 18 4:19 PM

Update
Stoploss Hit
Exit Price
₹2,165
@RISHABHTYAGI • Reputation: 4,623

*Once divislab breaks 2134 fut we may see more fall in it*
Like
reply
Reply
@RISHABHTYAGI • Reputation: 4,623

**Divis lab now ready to break day low guys**
Like
reply
Reply
@RISHABHTYAGI • Reputation: 4,623

Divis lab falling guys ready for more fall now
2134 till now
Like
reply
Reply
@RISHABHTYAGI • Reputation: 4,623

**Sell sell divislab jackpot guys**
Like
reply
Reply
@tsr • Reputation: 1,822
DIVISLAB FEB20 FUT

Type
Sell
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,138
Price@Trade
₹2,136.1
Target Price
₹2,120
Stop Price
₹2,155
Valid Till
Feb 18, 2020 3:20 PM
Margin
₹151,741.91 approx for 400 Qty
Status
Exited
Exit Price
₹2,134
Net P&L
1.05% Profit
All the best
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 18 3:08 PM

Update
Trade Entered
Entry Price
₹2,138
rahul @tsr
Feb 18 3:10 PM

Update
Exited
Exit Price
₹2,134
Net P&L
1.05% Profit
@100billionclub • Reputation: 3,727
DIVISLAB FEB20 FUT

Type
Sell
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,133.7
Price@Trade
₹2,133.7
Target Price
₹2,080
Stop Price
₹2,180
Valid Till
Feb 24, 2020 3:20 PM
Margin
₹152,049.04 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹2,180
Net P&L
-12.18% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 19 8:58 PM

Update
Stoploss Hit
Exit Price
₹2,180
@tradingfab • Reputation: 815

14-02-20
DIVISLAB FEB CE 2180 (Intraday)
only above @ 35
Like
reply
Reply (5)
Latest replies
Sameer  @tradingfab
Feb 14 4:46 PM

High 36.50 🔥🔥🚀🚀
Sameer  @tradingfab
Feb 14 5:16 PM

High 38 🔥🔥🚀🚀
Sameer  @tradingfab
Feb 14 5:19 PM

High 40 🔥🔥🚀
Sameer  @tradingfab
Feb 14 5:19 PM

High 40.60 🔥🔥🚀🚀
Sameer  @tradingfab
Feb 14 5:34 PM

High 42 🚀🚀🚀🚀💥
@riz-rJLrkcRjS • Reputation: -1
DIVISLAB

Type
Buy
Instrument
DIVISLAB
Entry Price
₹2,137
Price@Trade
₹2,137
Target Price
₹2,149
Stop Price
₹2,125
Valid Till
Feb 13, 2020 3:20 PM
Margin
₹2,137 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹2,125
Net P&L
-0.56% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 13 3:31 PM

Update
Stoploss Hit
Exit Price
₹2,125
@Stockstudy8 • Reputation: 1,023

Twitter
Like
reply
Reply
@goenkaji • Reputation: -1,563

BUY DIVIS LAB 2132 ND SELL DR REDDY @3200 FOR 15 DAYS. BUY DIVIS LAB 2132 ND SELL DR REDDY @3200 FOR 15 DAYS
Like
reply
Reply
@pritpatel • Reputation: 3,508
DIVISLAB FEB20 2000 PE

Type
Buy
Instrument
DIVISLAB FEB20 2000 PE
Entry Price
₹14.05
Price@Trade
₹13.2
Target Price
₹40
Stop Price
₹7
Valid Till
Feb 27, 2020 3:20 PM
Margin
₹5,620 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹7
Net P&L
-50.18% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 12 5:49 PM

Update
Trade Entered
Entry Price
₹14.05
TrackerBot @trackerbot
Feb 14 2:49 PM

Update
Stoploss Hit
Exit Price
₹7
@ichimoku • Reputation: 3,626
DIVISLAB FEB20 FUT

Type
Buy
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,148.35
Price@Trade
₹2,148.35
Target Price
₹2,170
Stop Price
₹2,143.5
Valid Till
Feb 12, 2020 3:20 PM
Margin
₹152,337.72 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹2,143.5
Net P&L
-1.27% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 12 3:55 PM

Update
Stoploss Hit
Exit Price
₹2,143.5
@marketbull • Reputation: -12,848
DIVISLAB FEB20 FUT

Type
Buy
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,147.5
Price@Trade
₹2,147.5
Target Price
₹2,165
Stop Price
₹2,130
Valid Till
Feb 12, 2020 3:20 PM
Margin
₹152,295.3 approx for 400 Qty
Status
Exited
Exit Price
₹2,140.2
Net P&L
-1.92% Loss
Like
reply
Reply (1)
Latest replies
BULL KING @marketbull
Feb 12 4:50 PM

Update
Exited
Exit Price
₹2,140.2
Net P&L
-1.92% Loss

2100 PE 33/35
Sl-20 TRG 40/50/65/80/100
Like
reply
Reply (1)
Latest replies
PROFITMUDRA STOCKS @rajmudra
Feb 12 6:01 PM

First target achieve👉👍 43+💚💚😘
@KetanT • Reputation: 179
DIVISLAB

Type
Buy
Instrument
DIVISLAB
Entry Price
₹2,175
Price@Trade
₹2,171.65
Target Price
₹2,190
Stop Price
₹2,160
Valid Till
Feb 12, 2020 3:20 PM
Margin
₹2,175 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹2,160
Net P&L
-0.69% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 12 3:00 PM

Update
Trade Entered
Entry Price
₹2,175
TrackerBot @trackerbot
Feb 12 3:47 PM

Update
Stoploss Hit
Exit Price
₹2,160
@Tamilrockers • Reputation: 4,768
DIVISLAB FEB20 2000 CE

Type
Sell
Instrument
DIVISLAB FEB20 2000 CE
Entry Price
₹152
Price@Trade
₹152.45
Target Price
₹22
Stop Price
₹177
Valid Till
Feb 27, 2020 3:20 PM
Status
Expired before entry
All the best
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 11 9:11 PM

Update
Expired before entry
Price @ Update
₹154.85

DIVISLAB - chart - 593802
Good signal,, but...
Like
reply
Reply
@tradingwiz • Reputation: 626

DIVISLAB - chart - 592741
Levels Mentioned on chart. Kindly Refer
Like
reply
Reply
@newsbot • Reputation: 2,308
Buy Divi’s Laboratories target of Rs 2200: Sharekhan
Sharekhan is bullish on Divi’s Laboratories has recommended buy rating on the stock with a target price of Rs 2200 in its research report dated February 06, 2019.
Moneycontrol
Like
reply
Reply
@chaudhary • Reputation: -140
DIVISLAB FEB20 FUT

Type
Buy
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,080.25
Price@Trade
₹2,080.25
Target Price
₹2,100
Stop Price
₹2,067
Valid Till
Feb 11, 2020 3:20 PM
Margin
₹147,821.47 approx for 400 Qty
Status
Target Achieved
Exit Price
₹2,100
Net P&L
5.34% Profit
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 11 2:47 PM

Update
Target Achieved
Exit Price
₹2,100
DIVISLAB FEB20 FUT

Type
Buy
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,086
Price@Trade
₹2,086
Target Price
₹2,188
Stop Price
₹2,050
Valid Till
Feb 27, 2020 3:20 PM
Margin
₹147,984.08 approx for 400 Qty
Status
Exited
Exit Price
₹2,103.25
Net P&L
4.66% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹2,103.25
Net P&L
4.66% Profit
@hidden • Reputation: 4,267

DIVIS LABS ON FIRE WITH BIG BREAKOUT....... ENJOYYYYYYYYYYYY MONEY RAIN WITH HIDDEN GEM 💪💪💪💪........ DON'T PLAY IF YOU HAVE NOT PERFECT ENTRY AND NOT PERFECT EXIT LEVELS....
Like
reply
Reply
@Tamilrockers • Reputation: 4,768
DIVISLAB FEB20 FUT

Type
Sell
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,068
Price@Trade
₹2,066
Target Price
₹2,054
Stop Price
₹2,079
Valid Till
Feb 7, 2020 3:20 PM
Margin
₹144,989.63 approx for 400 Qty
Status
Validity Over
Exit Price
₹2,075.25
Net P&L
-2% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 7 6:40 PM

Update
Trade Entered
Entry Price
₹2,068
TrackerBot @trackerbot
Feb 7 8:50 PM

Update
Validity Over
Exit Price
₹2,075.25
Net P&L
-2% Loss
@newsbot • Reputation: 2,308
Divis Labs Standalone December 2019 Net Sales at Rs 1,390.49 crore, up 3.54% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Divis Labs Consolidated December 2019 Net Sales at Rs 1,396.26 crore, up 2.67% Y-o-Y
Moneycontrol
Like
reply
Reply
Pankaj Bhardwaj in DIVISLAB
JACKPOT CALL: SELL DIVISLAB FUT @ 2062, YES KE...

made low of 2005..after my sell call
Like
reply
Reply
@pritpatel • Reputation: 3,508

Net sales rose 2.7% year-on-year (YoY) to Rs 1,396.26 crore in Q3 FY20. The result was announced after market hours yesterday, 5 February 2020.
Profit before Tax fell 6.7% to Rs 487.32 crore YoY. Current tax fell 5.6% to Rs 122.31 crore during the period under review.
The United ...
Read more...
Like
reply
Reply

JACKPOT CALL: SELL DIVISLAB FUT @ 2062, YES KEEP SL DAY HIGH 2090 & GO SHORT,
BIG PANIC ON CARD
Like
reply
Reply
@newsbot • Reputation: 2,308
Divis Labs Consolidated December 2019 Net Sales at Rs 1,396.26 crore, up 2.67% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Divis Labs Standalone December 2019 Net Sales at Rs 1,390.49 crore, up 3.54% Y-o-Y
Moneycontrol
Like
reply
Reply
@pyramidstock • Reputation: 2,476
Pyramidstock in DIVISLAB
buy divislab cmp 1980 sl 1950 tgt 2050-2080 res...

2085 from 1980 enjoy
Like
reply
Reply
@hidden • Reputation: 4,267
DIVISLAB FEB20 FUT

Type
Buy
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,059  ₹2,061
Price@Trade
₹2,061
Target Price
₹2,180
Stop Price
₹1,945  ₹1,978
Valid Till
Feb 27, 2020 3:20 PM
Margin
₹142,069.08 approx for 400 Qty
Status
Exited
Exit Price
₹2,097.1
Net P&L
10.16% Profit
Like
reply
Reply (4)
Latest replies
HIDDEN GEM @hidden
Feb 6 5:05 PM

Update
Entry Price Modified
Price @ Update
₹2,061
Original Entry Price
₹2,059
New Entry Price
₹2,061
TrackerBot @trackerbot
Feb 6 5:06 PM

Update
Trade Entered
Entry Price
₹2,061
HIDDEN GEM @hidden
Feb 6 7:26 PM

Update
Stoploss Trailed
Price @ Update
₹2,016.95
Original SL
₹1,945
New SL
1978.0
HIDDEN GEM @hidden
Feb 10 2:49 PM

Update
Exited
Exit Price
₹2,097.1
Net P&L
10.16% Profit

BRIEF-India's Divi's Labs Dec-Quarter Profit Falls - Reuters
05-Feb-2020 07:47:06 PM
Feb 5 (Reuters) - Divi's Laboratories Ltd DIVI.NS:
DEC-QUARTER CONSOL PROFIT 3.59 BILLION RUPEES VERSUS 3.90 BILLION RUPEES YEAR AGO
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 13.96 BILLION RUPE...
Read more...
Like
reply
Reply
@pritpatel • Reputation: 3,508
DIVISLAB FEB20 2000 CE

Type
Buy
Instrument
DIVISLAB FEB20 2000 CE
Entry Price
₹105
Price@Trade
₹109
Target Price
₹150
Stop Price
₹85
Valid Till
Feb 7, 2020 3:20 PM
Margin
₹42,000 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹85
Net P&L
-19.05% Loss
Like
reply
Reply (4)
Latest replies
TrackerBot @trackerbot
Feb 6 3:39 PM

Update
Trade Entered
Entry Price
₹105
PRIT PATEL @pritpatel
Feb 6 3:41 PM

94 to -109♈️🚀🚀🚀🚀
PRIT PATEL @pritpatel
Feb 6 4:00 PM

110+++🚀🚀🚀🚀
TrackerBot @trackerbot
Feb 6 4:32 PM

Update
Stoploss Hit
Exit Price
₹85
@Tamilrockers • Reputation: 4,768
DIVISLAB FEB20 FUT

Type
Sell
Instrument
DIVISLAB FEB20 FUT
Entry Price
₹2,056
Price@Trade
₹2,052
Target Price
₹2,023
Stop Price
₹2,073
Valid Till
Feb 6, 2020 3:20 PM
Margin
₹141,611.5 approx for 400 Qty
Status
Stoploss Hit
Exit Price
₹2,073
Net P&L
-4.8% Loss
All the best
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 6 3:35 PM

Update
Trade Entered
Entry Price
₹2,056
TrackerBot @trackerbot
Feb 6 3:36 PM

Update
Stoploss Hit
Exit Price
₹2,073
@Stockstudy8 • Reputation: 1,023

Twitter

Boom boom Only Divislabbb
#Divislabbbbbbbb😍😍😍😍
Near to Our Tgt of 2100 ..
.Start booking
At Record Lifehigh today
1775>>> 2055++
16%Up in 1.5month
#Largecap #Pharma #niftypharma #nse #Breakout #technicalanalysis
Reco👇
https://twitter.com/Stockstudy8/status/1197144851...
Read more...
Like
reply
Reply
@pyramidstock • Reputation: 2,476
Pyramidstock in DIVISLAB
divislab 2100 call cmp 21 sl 8 tgt 40

34.80 book profit
Like
reply
Reply
@bumblebee • Reputation: 564
Bumblebee OPTION in DIVISLAB
42 high more to come tmrw 🚀

46 high🚀
Hold with Sl
4k profits already booked
Like
reply
Reply
@bumblebee • Reputation: 564
Bumblebee OPTION in DIVISLAB
Divislab 1900PE near 35 SL 10✌️

42 high more to come tmrw 🚀
Like
reply
Reply
@pyramidstock • Reputation: 2,476

buy divislab cmp 1980 sl 1950 tgt 2050-2080 result today
Like
reply
Reply
@bumblebee • Reputation: 564

Divislab 1900PE near 35

SL 10✌️
Like
reply
Reply
@pyramidstock • Reputation: 2,476

divislab 2100 call cmp 21 sl 8 tgt 40
Like
reply
Reply
@sriharinune • Reputation: 5,824
DIVISLAB

Type
Sell
Instrument
DIVISLAB
Entry Price
₹1,956
Price@Trade
₹1,973.65
Target Price
₹1,944
Stop Price
₹1,962
Valid Till
Feb 5, 2020 3:20 PM
Margin
₹1,956 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹1,962
Net P&L
-0.31% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 5 8:27 PM

Update
Trade Entered
Entry Price
₹1,956
TrackerBot @trackerbot
Feb 5 8:27 PM

Update
Stoploss Hit
Exit Price
₹1,962
  • DIVISLAB - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization45,211.44
    Enterprise Value45,212.24
    Price to Earnings33.24
    Price to Book Value6.48
    Return on Capital Employed0.2
    Return on Equity0.15
    Face Value2
    Dividend Yield0.01
  • DIVISLAB Share Price - Technicals

    keyboard_arrow_down
    DIVISLAB - 52 Week High₹2,236.4
    DIVISLAB - 52 Week Low₹1,466
  • DIVISLAB - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    19-Aug-19SharekhanBuy1,800
    12-Aug-19Karvy Stock BrokingHold1,744
    28-May-19ICICIdirect.comHold1,780
    4-Feb-19ICICIdirect.comBuy1,800
    5-Dec-18Axis DirectBuy1,600
    DIVISLAB Brokerage Price Target
  • DIVISLAB Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 202199.52236.42156.852169.35
    Feb 19217021952155.752185.85
    Feb 182154.852180.22142.52175.25
    Feb 17215821702133.62154.85
    Feb 142169.2521902135.72146.45
  • DIVISLAB Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹2,050.67
    30 Day Moving Average₹1,993.87
    50 Day Moving Average₹1,929.67
    100 Day Moving Average₹1,830.45
    200 Day Moving Average₹1,721.61
  • DIVISLAB - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue3,8164,023.47-0.05
    Operating Profit1,2521,438.85-0.13
    Profit Before Tax1,2191,388.23-0.12
    Net Income8701,053.27-0.17
  • DIVISLAB - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds6,9735,9600.17
    Total Liabilities1,0678610.24
    Total Assets8,0406,8210.18
  • DIVISLAB - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity7651,148.05-0.33
    Cash from Investing Activity-476-1,134.08-0.58
    Cash from Financing Activity-314-9.3132.73
    Net Cash Flow-254.66-6.36
  • DIVISLAB - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.130.17
    Return on Equity0.150.19
    Return on Capital Employed0.20.26
  • DIVISLAB - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.24
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.13
    3 Year CAGR Growth in Net Income0.03
    3 Yr CAGR Growth - Diluted EPS-0.49
  • DIVISLAB - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.79
    5 Year CAGR Growth in Operating Profit0.52
    5 Year CAGR Growth in EBIDTA0.57
    5 Year CAGR Growth in Net Income0.42
    3 Yr CAGR Growth - Diluted EPS-0.29
  • DIVISLAB - Recent News

    keyboard_arrow_down
    NewsBot
    Feb 10 9:23 PM
    Buy Divi’s Laboratories target of Rs 2200: Sharekhan
    Moneycontrol
    NewsBot
    Feb 7 5:33 PM
    Divis Labs Standalone December 2019 Net Sales at Rs 1,390.49 crore, up 3.54% Y-o-Y
    Moneycontrol
    NewsBot
    Feb 7 5:33 PM
    Divis Labs Consolidated December 2019 Net Sales at Rs 1,396.26 crore, up 2.67% Y-o-Y
    Moneycontrol
    NewsBot
    Feb 6 5:33 PM
    Divis Labs Consolidated December 2019 Net Sales at Rs 1,396.26 crore, up 2.67% Y-o-Y
    Moneycontrol
    NewsBot
    Feb 6 5:28 PM
    Divis Labs Standalone December 2019 Net Sales at Rs 1,390.49 crore, up 3.54% Y-o-Y
    Moneycontrol
    NewsBot
    Feb 5 2:13 PM
    Market Headstart: Nifty likely to reclaim 12,000; investors hope for more stimulus in China
    Moneycontrol
    NewsBot
    Feb 1 3:53 PM
    Divis Labs share price gains 2% after no USFDA observations for Chippada unit
    Moneycontrol
    NewsBot
    Feb 1 1:18 PM
    Stocks in the news: HUL, ITC, Divis Lab, Castrol, Power Grid, JSPL, IndoStar Capital
    Moneycontrol
    NewsBot
    Jan 31 4:53 PM
    Low rollover seen ahead of Budget; Nifty rollovers at 66.30% for Feb series
    Moneycontrol
    NewsBot
    Oct 17 6:48 PM
    'Nifty can rally towards 11,700 if index sustains above 11,400; 5 stocks to bet on'
    Moneycontrol
  • DIVISLAB - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
    Apollo Hospitals Enterprise Ltd. Sec...
  • DIVISLAB - More Information

    keyboard_arrow_down

    Divi's Laboratories Ltd:
    Divi's Laboratories Limited is incorporated back in 1990 and headquartered in Hyderabad, Telangana, India. This company, at its initial stage of the foundation, was named as Divi's Research Centre and later on in 1994 was changed to Divi's Laboratories Limited. This company is responsible for manufacturing and selling APIs or active pharmaceutical ingredients along with intermediates for generics. This is carried on in India, other parts of Asia, US, Europe and several other parts of the world.
    It offers the different unit for building compounds like several carotenoids inclusive of beta-carotene, astaxanthin, canthaxanthin, lycopene, and apocarotenol. Other than this it also offers groups for building protects amino acids like FMOC, BCZ and BOC as well as for chiral ligands and peptide and nucleotides.
    Apart from this, it also customizes the synthesis of several active pharmaceutical ingredients along with advanced forms of discovered compounds for other pharmaceutical companies. It also offers full-time contract-based research on development processes to identify new compounds.
    Company Information:
    Between the years 1991-1993, Divi's developed multiple bulk actives and other intermediates products for several other manufacturing companies. It received its ISO-9002 certification with compliance to SGS-Yarsley belonging to the UK, back in 1997. With the following two years, in 1999, the company received a Certificate of Suitability from the European Directorate for the production of Naproxen.
    For the company's system of occupational health and safety management, it received the OHSAS-18001 certificate. It was given to them by BVQI from London in 2001. In the year 2002, Divi's set up their Unit number II, a manufacturing facility in Chippada. In the following year in 2003, the company inaugurated a new research centre in Vizag, named DRC-Vizag. This was built for fundamental research in specific core segments.
    In the year 2004, Rs 3035.21 lakh was invested by Divi's for adding machines to both of their units in Unit-I (Choutuppal) and Unit-II (Chippada), and this was accounted for in their capital expenditure. In 2006, it received an approval letter from the Ministry of Commerce in India. This was for setting up a Special Economic Zone for multiple pharma based ingredients at Chippada, Vizag which led the company to invest Rs 200 crore.
    During the year 2008-09, the company's portfolio added a total of 9 products. Four of these nine products consisted of generic APIs, and the rest belonged to intermediates and custom synthesis of APIs. Another seven products were added to the company portfolio in 2009-2010. Out of these seven products, 2 were generic APIs along with intermediates, while the rests were intermediates and custom synthesis APIs. During the year 2012-13, the company went on to add another nine products out of which three of these were generic APIs along with intermediates, and the rest six were custom synthesis APIs and intermediates.
    On 19 February 2016, the company went through an inspection by US-FDA for its second unit in Chapada, Bhemunipatam near Vizag and was this event was successful which happened without any observation. In 2017, on 18 November, the company announced that it had received EIR (Establishment Inspection Report) from FDA (US) for their second unit in Vizag. On 16 May 2018, Divi's Laboratories stated that their Unit-I in Telangana was under the inspection of the US-FDA starting from 14 May 2018 to 16 May 2018. The review conducted was a cGMP general inspection done by the FDA.
    The company is one of the biggest pharmaceutical companies in the country, which currently has a portfolio of 120 products. It has presently products belonging to multiple therapeutic aspects. It has a total of four manufacturing units with a developing market presence in several countries. Their first facility is located in Yadadri Bhuvanagiri District; Telangana consists of 11 blocks for multipurpose production along with finishes product spaces for APIs.
    How Divi’s Laboratories, is categorised as a Pharmaceutical and Health care Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Divi's Laboratories is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Divi’s Laboratories, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.